Etrasimod

PBAC's latest decision on Etrasimod: Recommended with restriction (2024). Considered for Treatment of patients 16 years and older with moderate to severe ulcerative colitis (MSUC).

Eligible population

Adults and adolescents aged 16 years and older with moderate to severe ulcerative colitis (MSUC) who have failed standard therapies including 5-aminosalicylates, azathioprine or 6-mercaptopurine, or oral corticosteroids with thiopurine agents, with a Mayo clinic score ≥6 or partial Mayo score ≥6 (with rectal bleeding and stool frequency subscores both ≥2).

Therapy area

Gastroenterology

Line of therapy

Later-line

Evidence base

RCT

Primary endpoint

Clinical remission and clinical response

Key trials

ELEVATE UC 12, ELEVATE UC 52, True North, Touchstone, ACT 1, ACT 2, Jiang 2015, Kobayashi 2016, Remicade, ULTRA 1, ULTRA 2, Suzuki 2014

Comparator

ozanimod (primary)

Economic model

Cost-minimisation

ICER note

Cost-minimisation approach; no ICER calculated. Economic evaluation based on cost equivalence between ETR and OZA at equi-effective doses over 104 weeks.

Similar precedents

• Ozanimod
  similarity 0.70
• Mirikizumab
  similarity 0.71
• Vedolizumab
  similarity 0.70
• Infliximab
  similarity 0.67
• Mesalazine
  similarity 0.68
• Balsalazide
  similarity 0.67